UnitedHealth and healthcare look set to outperform through year-end, helped by midterm-year seasonality and defensive appeal. Over the last 20 years healthcare has generally done well from July through December in midterm election years. If the S&P 500 rolls into a bear market, UnitedHealth could outperform as investors rotate into defensive sectors. The bull case holds if medical cost ratios fall from AI and GLP-1 use and institutions rotate back into healthcare. x.com 

UnitedHealth should outperform through year-end on midterm-year seasonality and as a defensive leader if markets weaken. Over the last 20 years, healthcare has generally done well from July through December in midterm years, and if the S&P 500 rolls into a bear market, investors should rotate into defensives led by UNH. The bull case also rests on AI and GLP-1 use lowering the medical cost ratio and institutions returning to healthcare. The war has made everything more volatile. x.com 

UnitedHealth's rebound still has a Medicaid problem because care costs are outpacing state funding. Q3 operating profit rose to $6.6bn from $4.3bn a year earlier, but Medicaid is still expected to lose money in 2026. x.com 

Health care and energy are among the best places to be in a midterm year, with AI keeping tech, industrials and utilities stronger than usual. Since 1994, health care has beaten the S&P 500 by nearly 17% on average in midterm years, averaging 10.7% versus energy's 8.9%. The playbook favors health care, energy, staples and utilities into the vote, then tech, industrials and growth names such as Nvidia, Microsoft, Tesla and Amazon after it, with AI infrastructure the new post-midterm rotation. … Show more

Healthcare is the clearest place money is moving, and UnitedHealth is the preferred name here. It beat earnings and raised its 2026 profit forecast. x.com 

Healthcare looks attractive as volatility has eased in recent weeks while inflows stay steady. Merck is the best-looking pharma play, pharma and biotech are favored, and the broad healthcare sector covers all the bases. x.com 

Healthcare's recovery is still in early innings because rotation keeps flowing in. Investors are dumping software for hardware, and those who see hardware as saturated are moving into healthcare as a defensive, long-undervalued sector; the richer hardware gets, the stronger that pull. Oscar Health hit its short-term target early and can reach $40 if this quarter resembles Q1. UnitedHealth, near $410, can aim for $425 to $450 on another beat and raise in Q2. x.com 

Healthcare and biotech should see a massive capital rotation as aging populations seek to cheat death through cellular immunotherapy, nootropics and personalized medicine, and healthcare holds up in recessions while tech tanks. Eli Lilly is the best big-cap expression of the trade. Money should flow to concierge practices for a K-shaped economy and to new, expensive tailored drugs, while consumer outlets like CVS likely underperform. x.com  x.com  x.com 

TransMedics, Hims & Hers, Harrow, PROCEPT BioRobotics, ClearPoint Neuro, Alphatec and Compass Pathways can double in 2–3 years and triple in 3–5 because these small- and mid-cap healthcare names trade at only 2–3x next-12-month revenue. Software and cloud stocks people are chasing at 20–30x make such returns hard. Alphatec looks attractive after its earnings selloff, while Compass is very speculative and should not be chased. x.com 

Capital is rotating out of AI capex into areas it starved for two years. Health care, airlines, defense and metals are where the market wants to be for the six weeks to the December 9 Fed meeting; gold and silver are bought on every dip. Risk is still being taken elsewhere: if S&P futures hold 7,700, the rotation carries the index; if they lose it, this was a correction in disguise. x.com